Biomarkers of rejection in liver transplantation

Giovanni Perottino, Claire Harrington, Josh Levitsky*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Purpose of reviewLiver transplantation is a lifesaving therapy for thousands of individuals with end-stage liver disease across the world. Allograft rejection, which is traditionally detected through an invasive graft biopsy, is a major complication for liver transplant recipients in the postoperative period. Biomarkers represent a relatively newer and safer means of detecting and predicting transplant rejection when compared with the current standard of care: liver biopsy. This review serves to compile recent progress in the field of biomarker discovery in liver allograft rejection.Recent findingsSeveral promising biomarkers exist in the field of liver transplant rejection. Recent developments include blood genomic assays measuring miRNA, mRNA and donor-derived cell-free DNA. Additionally, serum levels of cytokines, proteoforms, donor-specific antibodies and immunophenotyping have shown promising results in predicting rejection pre and/or posttransplant.SummaryBiomarkers represent a novel method of predicting the risk of developing allograft rejection. The findings discussed in the studies outlined in this review are promising in the potential to improve patient management, reduce complications from over- or under-immunosuppression, and ultimately enhance outcomes.

Original languageEnglish (US)
Pages (from-to)154-158
Number of pages5
JournalCurrent opinion in organ transplantation
Issue number2
StatePublished - Apr 1 2022


  • biomarker
  • biopsy
  • liver transplant
  • rejection

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation


Dive into the research topics of 'Biomarkers of rejection in liver transplantation'. Together they form a unique fingerprint.

Cite this